Literature DB >> 22052383

Bipolar depression: an evidence-based approach.

Claudia F Baldassano1, Alexander Hosey, Jordan Coello.   

Abstract

Bipolar disorder is a complex, multidimensional illness that is often difficult to treat. Unfortunately, bipolar patients are much more likely to experience depression, which is all too often severe and a potentially lethal phase of the illness. In addition, pharmacotherapies with strong evidence for bipolar depression are limited. Most treatments are based on unsupported extrapolation from the treatment of unipolar depression or are derived largely from the clinical practice experience. In this article, we focus on the treatment of bipolar depression, with particular focus on evidence from the existing literature, to help guide readers in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22052383     DOI: 10.1007/s11920-011-0238-7

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  39 in total

1.  Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.

Authors:  Andrew A Nierenberg; Michael J Ostacher; Joseph R Calabrese; Terence A Ketter; Lauren B Marangell; David J Miklowitz; Sachiko Miyahara; Mark S Bauer; Michael E Thase; Stephen R Wisniewski; Gary S Sachs
Journal:  Am J Psychiatry       Date:  2006-02       Impact factor: 18.112

2.  Functional impairment and disability across mood states in bipolar disorder.

Authors:  Adriane R Rosa; María Reinares; Erin E Michalak; C Mar Bonnin; Brisa Sole; Carolina Franco; Mercè Comes; Carla Torrent; Flávio Kapczinski; Eduard Vieta
Journal:  Value Health       Date:  2010-12       Impact factor: 5.725

3.  A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).

Authors:  Susan L McElroy; Richard H Weisler; William Chang; Bengt Olausson; Björn Paulsson; Martin Brecher; Vasavan Agambaram; Charles Merideth; Arvid Nordenhem; Allan H Young
Journal:  J Clin Psychiatry       Date:  2010-01-26       Impact factor: 4.384

4.  Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.

Authors:  Michael E Thase; Alan Jonas; Arif Khan; Charles L Bowden; Xiaoling Wu; Robert D McQuade; William H Carson; Ronald N Marcus; Randall Owen
Journal:  J Clin Psychopharmacol       Date:  2008-02       Impact factor: 3.153

5.  Suicide risk in bipolar disorder during treatment with lithium and divalproex.

Authors:  Frederick K Goodwin; Bruce Fireman; Gregory E Simon; Enid M Hunkeler; Janelle Lee; Dennis Revicki
Journal:  JAMA       Date:  2003-09-17       Impact factor: 56.272

6.  A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.

Authors:  Roger S McIntyre; Miriam Cohen; Jun Zhao; Larry Alphs; Thomas A Macek; John Panagides
Journal:  Bipolar Disord       Date:  2009-11       Impact factor: 6.744

Review 7.  Clinical studies on the use of lamotrigine in bipolar disorder.

Authors:  J R Calabrese; D J Rapport; M D Shelton; M Kujawa; S E Kimmel
Journal:  Neuropsychobiology       Date:  1998-10       Impact factor: 2.328

8.  Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder.

Authors:  Ralph W Kupka; Lori L Altshuler; Willem A Nolen; Trisha Suppes; David A Luckenbaugh; Gabriele S Leverich; Mark A Frye; Paul E Keck; Susan L McElroy; Heinz Grunze; Robert M Post
Journal:  Bipolar Disord       Date:  2007-08       Impact factor: 6.744

9.  Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.

Authors:  Carlos A Zarate; Jennifer L Payne; Jaskaran Singh; Jorge A Quiroz; David A Luckenbaugh; Kirk D Denicoff; Dennis S Charney; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2004-07-01       Impact factor: 13.382

10.  Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study.

Authors:  E Vieta; J R Calabrese; J M Goikolea; S Raines; W Macfadden
Journal:  Bipolar Disord       Date:  2007-06       Impact factor: 6.744

View more
  1 in total

Review 1.  Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews.

Authors:  Michele Fornaro; Domenico De Berardis; Giampaolo Perna; Marco Solmi; Nicola Veronese; Laura Orsolini; Elisabetta Filomena Buonaguro; Felice Iasevoli; Cristiano André Köhler; André Ferrer Carvalho; Andrea de Bartolomeis
Journal:  Biomed Res Int       Date:  2017-05-09       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.